Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

0.8400
-0.0499-5.61%
Post-market: 0.8398-0.0002-0.02%18:49 EDT
Volume:71.46K
Turnover:62.28K
Market Cap:22.39M
PE:-2.94
High:0.9098
Open:0.8982
Low:0.8400
Close:0.8899
52wk High:3.40
52wk Low:0.8208
Shares:26.65M
Float Shares:21.83M
Volume Ratio:0.73
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.3933
ROE:-69.86%
ROA:-22.85%
PB:2.18
PE(LYR):-2.14

Loading ...

Appeals Court Revives Lawsuits Alleging Tylenol Causes Autism and ADHD

Dow Jones
·
Jul 14

Axsome Therapeutics: SUNOSI IP De-Risked, ADHD Phase 3 Expansion Supports Reaffirmed $290 12-Month Price Target and Buy Rating

TIPRANKS
·
Jul 08

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

GlobeNewswire
·
Jul 07

Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

GlobeNewswire
·
Jul 06

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves

Simply Wall St.
·
Jul 06

ABVC Biopharma Replaces Auditor Simon & Edward with Kreit & Chiu for 2026 Audit

Reuters
·
Jul 03

Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®

GlobeNewswire
·
Jul 02

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

GlobeNewswire
·
Jun 29

BlinkLab Says European ADHD Study Completes Participant Recruitment, Shares Fall 3%

MT Newswires Live
·
Jun 26

BlinkLab Nears Final Analysis in European ADHD Study After Completing Data Collection

TIPRANKS
·
Jun 26

Analyst Raises 12‑Month Target and Reiterates Buy on Definium After Best-in-Class MDD Trial Results and Reduced Risk Adjustment

TIPRANKS
·
Jun 23

Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk

TIPRANKS
·
Jun 22

Cingulate Faces FDA Delay But Maintains ADHD Drug Plans

TIPRANKS
·
Jun 02

Cingulate Receives Complete Response Letter from FDA for CTx-1301

GlobeNewswire
·
Jun 02

Collegium Pharma Leans on ADHD to Drive Growth

TIPRANKS
·
May 20

ABVC BioPharma Q1 EPS $(0.06), Same YoY

Benzinga Earnings
·
May 18

ABVC Biopharma Q1 FY26 net loss widens 79% to $1.69 million

Reuters
·
May 18

ABVC BioPharma delays filing quarterly report for period ended March 31, 2026

Reuters
·
May 16

Press Release: Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301

Dow Jones
·
May 14

Collegium Pharmaceutical Completes AZSTARYS ADHD Business Acquisition

TIPRANKS
·
May 12